News
14h
Verywell Health on MSNNot Enough Adults Are Getting the RSV Vaccine. Here's Why That MattersFact checked by Nick Blackmer The Centers for Disease Control and Prevention (CDC) has expanded the RSV vaccine ...
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...
1h
Vietnam Investment Review on MSNArkBio s RSV Drug Added to WHO Pediatric Priority ListIn the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization ...
Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...
In the newly released 'Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report' by Global ...
Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...
Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results